AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

172.1 USD

Average target price

183.2 USD

Spread / Average Target

+6.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+11.07%	303B
ELI LILLY AND COMPANY	+51.99%	803B
JOHNSON & JOHNSON	-5.72%	351B
MERCK & CO., INC.	+18.94%	324B
ASTRAZENECA PLC	+16.96%	243B
ROCHE HOLDING AG	+2.25%	228B
NOVARTIS AG	+11.15%	217B
AMGEN INC.	+7.59%	164B
PFIZER, INC.	-3.65%	155B
SANOFI	-1.84%	117B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 20/06/2024 BST			5-day change	1st Jan Change
172.1 ^USD	+0.45%		+3.34%	+11.07%

06-20	AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis	MT
06-20	US FDA proposes to remove switching study requirement for biosimilars	RE

AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis	06-20	MT
US FDA proposes to remove switching study requirement for biosimilars	06-20	RE
AbbVie Inc. Announces Board of Directors Changes	06-20	CI
AbbVie: FDA approval in ulcerative colitis	06-19	CF
AbbVie's Skyrizi Gets FDA Approval to Treat Certain Instances of Ulcerative Colitis	06-18	DJ
Piper Sandler Adjusts Price Target on AbbVie to $190 From $185	06-18	MT
Future prospects for AI	06-18
AbbVie Says Investors Should Sit Out Tutanota Mini-Tender Offer	06-14	MT
AbbVie inks immune disorder drug licensing deal with China's FutureGen	06-13	RE
AbbVie, FutureGen in License Pact for Inflammatory Bowel Disease Drug	06-13	DJ
AbbVie, FutureGen to Develop Potential Inflammatory Bowel Disease Treatment	06-13	MT
Transcript : AbbVie Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:00 AM	06-12
Alvotech Expands Alliance with STADA to Include Denosumab Biosimilar	06-11	MT
Three companies to bet on medical AI	06-10
Global markets live: ABB, Roche, Microsoft, Apple, Tesla...	06-10
AbbVie's Blood Cancer Treatment Receives Scottish Approval	06-10	MT
Top law firms in US opioid lawsuits to get hundreds of millions in fees	06-07	RE
Calico Life Sciences LLC and AbbVie Announce That Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease Has Been Selected for the FDA Start Pilot Program	06-07	CI
AbbVie's tight grip on Humira market raises concerns about biosimilars	06-07	RE
AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint	06-06	MT
AbbVie's ovarian cancer therapy succeeds in mid-stage trial	06-06	RE
AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha Expressing Platinum-Sensitive Ovarian Cancer	06-06	CI
Global markets live: Inditex, Intel, TSMC, Dollar Tree, AbbVie...	06-05
AbbVie Says First Patient Treated in Phase 3 Trial Assessing Potential Blood Cancer Treatment	06-05	MT
The odds of rates getting cut in 2024 may be better than you think	06-05